Clinical and pathological characteristics of peripheral T‐cell lymphomas in a Spanish population: a retrospective study

We investigated the clinicopathological features and prognostic factors of patients with peripheral T-cell lymphoma (PTCL) in 13 sites across Spain. Relevant clinical antecedents, CD30 expression and staining pattern, prognostic indices using the International Prognostic Index and the Intergruppo It...

Full description

Bibliographic Details
Authors: Rodríguez Pinilla, Socorro Maria, Domingo Domènech, Eva, Climent, Fina, Sánchez, Joaquín, Pérez Seoane, Carlos, López Jiménez, Javier, García Cosio, Mónica, Caballero, Dolores, Blanco Muñez, Oscar Javier, Carpio, Cecilia, Castellví, Josep, Martínez Pozo, Antonio, González Farré, Blanca, Bendaña, Angeles, Aliste, Carlos, González, Ana Julia, Gonzalez de Villambrosia, Sonia, Piris, Miguel A., Gómez Codina, Jose, Mayordomo Aranda, Empar, Navarro, Belen, Bellas, Carmen, Rodríguez, Guillermo, Borrero, Juan Jose, Ruiz Zorrilla, Ana, Grande, Marta, Montoto, Carmen, Cordoba, Raul
Format: article
Status:Published version
Publication Date:2020
Country:España
Institution:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repository:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/174243
Online Access:https://hdl.handle.net/2445/174243
Access Level:Open access
Keyword:Cèl·lules T
Limfomes
T cells
Lymphomas
Description
Summary:We investigated the clinicopathological features and prognostic factors of patients with peripheral T-cell lymphoma (PTCL) in 13 sites across Spain. Relevant clinical antecedents, CD30 expression and staining pattern, prognostic indices using the International Prognostic Index and the Intergruppo Italiano Linfomi system, treatments, and clinical outcomes were examined. A sizeable proportion of 175 patients had a history of immune-related disorders (autoimmune 16%, viral infections 17%, chemo/radiotherapy-treated carcinomas 19%). The median progression-free survival (PFS) and overall survival (OS) were 7·9 and 15·8 months, respectively. Prognostic indices influenced PFS and OS, with a higher number of adverse factors resulting in shorter survival (P < 0·001). Complete response (CR) to treatment was associated with better PFS (62·6 vs. 4 months; P < 0·001) and longer OS (67·0 vs. 7·3 months; P < 0·001) compared to no CR. CD30 was expressed across all subtypes; >15% of cells were positive in anaplastic lymphoma kinase-positive and -negative anaplastic large-cell lymphoma and extranodal natural killer PTCL groups. We observed PTCL distribution across subtypes based on haematopathological re-evaluation. Poor prognosis, effect of specific prognostic indices, relevance of histopathological sub-classification, and response level to first-line treatment on outcomes were confirmed. Immune disorders amongst patients require further examination involving genetic studies and identification of associated immunosuppressive factors.

Similar Items